Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Recursion Pharmaceuticals Inc

Healthcare US RXRX

3.8599USD
0.39(11.24%)

Last update at 2026-06-04T18:14:00Z

Day Range

3.454.04
LowHigh

52 Week Range

4.9716.75
LowHigh

Fundamentals

  • Previous Close 3.47
  • Market Cap2177.00M
  • Volume31135577
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-349.54499M
  • Revenue TTM46.23M
  • Revenue Per Share TTM0.21
  • Gross Profit TTM -164.12800M
  • Diluted EPS TTM-1.63

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -239.47600M -186.47900M -87.00600M -61.87900M
Minority interest - - - -
Net income -239.42100M -178.07400M -87.88200M -62.52500M
Selling general administrative 81.60M 57.68M 25.26M 18.95M
Selling and marketing expenses - - - -
Gross profit -8.59400M 10.00M 3.41M 1.71M
Reconciled depreciation 11.76M 8.40M 4.44M 3.54M
Ebit -257.48300M -191.18000M -84.61500M -62.44100M
Ebitda -245.72700M -182.77500M -80.32100M -58.20000M
Depreciation and amortization 11.76M 8.40M 4.29M 4.24M
Non operating income net other - -3.70400M - -
Operating income -245.72700M -182.77500M -84.61500M -62.44100M
Other operating expenses 285.41M 192.78M 88.03M 64.15M
Interest expense 0.06M 2.95M 1.36M 0.64M
Tax provision - - - -
Interest income 6.25M 0.07M 0.34M 1.74M
Net interest income 6.20M -2.87900M -1.02400M 1.11M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.05500M -8.40500M 0.88M 0.65M
Total revenue 39.68M 10.00M 3.41M 1.71M
Total operating expenses 237.13M 192.78M 88.03M 64.15M
Cost of revenue 48.27M - - -
Total other income expense net 6.25M -3.70400M -2.39100M 0.56M
Discontinued operations - - - -
Net income from continuing ops -239.47600M -186.47900M -87.00600M -61.87900M
Net income applicable to common shares -239.47600M -186.47900M -87.00600M -61.87900M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 653.70M 701.29M 610.35M 298.58M 101.43M
Intangible assets 36.44M 1.31M 1.39M 2.49M -
Earning assets - - - - -
Other current assets 40.25M 15.87M 7.51M 2.15M 1.08M
Total liab 190.26M 215.48M 67.41M 504.87M 225.70M
Total stockholder equity 463.44M 485.81M 542.94M -206.28900M -124.26500M
Deferred long term liab - - 4.11M - -
Other current liab 46.63M 32.90M 32.33M 10.48M 4.88M
Common stock 0.00200M 0.00200M 0.00200M - -
Capital stock 0.00200M 0.00200M 0.00200M 0.00000M 0.00000M
Retained earnings -967.62200M -639.55600M -400.08000M -213.60100M -126.59500M
Other liab - 70.26M 10.78M 19.34M 2.28M
Good will 52.06M 0.80M 0.80M - -
Other assets 0.00000M 7.92M 8.72M 0.65M 0.66M
Cash 394.80M 549.91M 285.12M 262.13M 69.88M
Cash and equivalents - - - - -
Total current liabilities 93.17M 100.27M 46.66M 23.10M 6.68M
Current deferred revenue 36.43M 56.73M 10.00M 10.00M -
Net debt -344.12400M -498.90700M -273.63800M -246.46400M -53.71400M
Short term debt 6.16M 6.05M 1.51M 1.54M 0.54M
Short long term debt 0.04M 0.10M 0.09M 1.07M 0.08M
Short long term debt total 50.67M 51.01M 11.48M 15.66M 16.17M
Other stockholder equity 1431.06M 1125.36M 332.80M 7.31M 2.33M
Property plant equipment - 121.45M 64.72M 25.97M 24.37M
Total current assets 438.14M 569.81M 534.72M 269.48M 76.40M
Long term investments - - - - -
Net tangible assets - 483.70M 540.75M -208.77900M -124.26500M
Short term investments - 0.00000M 231.45M - -
Net receivables 3.09M 2.75M 9.09M 0.16M 0.15M
Long term debt 1.10M 0.54M 0.63M 11.41M 12.42M
Inventory -3.09400M 1.28M 1.55M 5.04M 5.29M
Accounts payable 3.95M 4.59M 2.82M 1.07M 1.26M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - -0.12600M -9.96200M -5.71500M
Additional paid in capital - - - - -
Common stock total equity - - 0.00200M - -
Preferred stock total equity - - - - -
Retained earnings total equity - - -400.08000M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.26M 7.92M 8.72M 0.65M 0.66M
Deferred long term asset charges - - - - -
Non current assets total 215.56M 131.47M 75.63M 29.11M 25.03M
Capital lease obligations 49.53M 50.37M 10.76M 3.17M 3.67M
Long term debt total - - 0.63M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 193.25M -231.94600M -8.74000M -3.91000M
Change to liabilities 112.09M 14.51M 26.48M -0.34000M
Total cashflows from investing activities 193.25M -271.74400M -8.74000M -3.91000M
Net borrowings -0.09000M -12.79800M 6.32M 0.70M
Total cash from financing activities 154.34M 458.54M 246.13M 120.41M
Change to operating activities -7.16600M 7.83M 4.36M 0.78M
Net income -239.47600M -186.47900M -87.00600M -61.87900M
Change in cash 263.76M 28.18M 192.00M 59.46M
Begin period cash flow 295.35M 267.17M 75.17M 15.71M
End period cash flow 559.11M 295.35M 267.17M 75.17M
Total cash from operating activities -83.52400M -158.61400M -45.39900M -57.04200M
Issuance of capital stock 143.71M 462.90M 239.13M 119.92M
Depreciation 11.76M 8.40M 4.44M 2.49M
Other cashflows from investing activities - - 0.59M 0.59M
Dividends paid - - - -
Change to inventory - 7.83M 4.36M -
Change to account receivables - 0.11M -0.00500M -0.02700M
Sale purchase of stock - 471.34M - -
Other cashflows from financing activities 10.72M 8.44M 246.21M 131.59M
Change to netincome 39.27M 19.77M 6.83M 1.39M
Capital expenditures 37.36M 39.80M 6.74M 3.91M
Change receivables - 0.11M - -
Cash flows other operating - -14.92900M - -
Exchange rate changes - - - -
Cash and cash equivalents changes - 28.18M - -
Change in working capital 104.92M -0.30600M 30.83M 0.41M
Stock based compensation 27.91M 14.84M 4.29M 1.39M
Other non cash items 11.37M 4.10M 0.28M -0.49900M
Free cash flow -120.88300M -198.41200M -52.13400M -60.95200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RXRX
Recursion Pharmaceuticals Inc		 0.39 11.24% 3.86 - - 44.27 4.26 37.26 -5.3145
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Recursion Pharmaceuticals Inc

41 South Rio Grande Street, Salt Lake City, UT, United States, 84101

Key Executives

Name Title Year Born
Dr. Christopher C. Gibson Ph.D. Co-Founder, CEO & Director 1983
Ms. Tina Marriott Larson COO & Pres 1975
Dr. Blake C. Borgeson Ph.D. Co-Founder & Director 1982
Dr. Michael Secora Ph.D. Chief Financial Officer 1983
Dr. Shafique Virani M.D. Interim Chief Medical Officer & Chief Bus. Officer 1971
Kevin Leggat VP of Fin. & Accounting NA
Mr. Benjamin Mabey M.S. Chief Technology Officer 1983
Mr. Jared Allenbach Sr. Director of Investor Relations NA
Ms. Louisa Daniels J.D., M.B.A. Chief Legal Officer & Gen. Counsel 1958
Mr. Ryan Kelly Chief Communications Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.